Inhibition of Proliferation and Induction of Apoptosis by 25-Hydroxyvitamin D3-3β-(2)-Bromoacetate, a Nontoxic and Vitamin D Receptor-Alkylating Analog of 25-Hydroxyvitamin D3 in Prostate Cancer Cells

The 25-hydroxyvitamin D3 (25-OH-D3) is a nontoxic and low-affinity vitamin D receptor (VDR)-binding metabolic precursor of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3]. We hypothesized that covalent attachment of a 25-OH-D3 analog to the hormone-binding pocket of VDR might convert the latter into transcriptionally active holo-form, making 25-OH-D3 biologically active. Furthermore, it might be possible to translate the nontoxic nature of 25-OH-D3 into its analog. We showed earlier that 25-hydroxyvitamin D3-3-bromoacetate (25-OH-D3-3-BE) alkylated the hormone-binding pocket of VDR. In this communication we describe that 10−6 mol/L of 25-OH-D3-3-BE inhibited the growth of keratinocytes, LNCaP, and LAPC-4 androgen-sensitive and PC-3 and DU145 androgen-refractory prostate cancer cells, and PZ-HPV-7 immortalized normal prostate cells with similar or stronger efficacy as 1,25(OH)2D3. But its effect was strongest in LNCaP, PC-3, LAPC-4, and DU145 cells. Furthermore, 25-OH-D3-3-BE was toxic to these prostate cancer cells and caused these cells to undergo apoptosis as shown by DNA-fragmentation and caspase-activation assays. In a reporter assay with COS-7 cells, transfected with a 1α,25-dihydroxyvitamin D3-24-hydroxylase (24-OHase)-construct and VDR-expression vector, 25-OH-D3-3-BE induced 24-OHase promoter activity. In a “pull down assay” with PC-3 cells, 25-OH-D3-3-BE induced strong interaction between VDR and general transcription factors, retinoid X receptor, and GRIP-1. Collectively, these results strongly suggested that the cellular effects of 25-OH-D3-3-BE were manifested via 1,25(OH)2D3/VDR signaling pathway. A toxicity study in CD-1 mice showed that 166 μg/kg of 25-OH-D3-3-BE did not raise serum-calcium beyond vehicle control. Collectively, these results strongly suggested that 25-OH-D3-3-BE has a strong potential as a therapeutic agent for androgen-sensitive and androgen-refractory prostate cancer.

[1]  Yigong Shi.  Caspase Activation Revisiting the Induced Proximity Model , 2004, Cell.

[2]  A. Ismail,et al.  Effect of cellular environment on the selective activation of the vitamin D receptor by 1alpha,25-dihydroxyvitamin D3 and its analog 1alpha-fluoro-16-ene-20-epi-23-ene-26,27-bishomo-25-hydroxyvitamin D3 (Ro-26-9228). , 2004, Molecular endocrinology.

[3]  G. Pirianov,et al.  Effects of Seocalcitol (EB1089) on Nitrosomethyl Urea-Induced Rat Mammary Tumors , 2003, Breast Cancer Research and Treatment.

[4]  N. Swamy,et al.  1α,25‐Dihydroxyvitamin D3‐3β‐(2)‐bromoacetate, an affinity labeling derivative of 1α,25‐dihydroxyvitamin D3 displays strong antiproliferative and cytotoxic behavior in prostate cancer cells , 2003 .

[5]  J. Dancey,et al.  A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma , 2003, British Journal of Cancer.

[6]  N. Weigel,et al.  p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. , 2003, Endocrinology.

[7]  H. DeLuca,et al.  A potent analog of 1α,25-dihydroxyvitamin D3 selectively induces bone formation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[8]  P. Hershberger,et al.  Vitamin D receptor: a potential target for intervention. , 2002, Urology.

[9]  John Calvin Reed,et al.  Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer. , 2002, Molecular cancer therapeutics.

[10]  M. Holick,et al.  25-Hydroxyvitamin D-1α-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[11]  Sándor Eckhardt,et al.  Recent progress in the development of anticancer agents. , 2002, Current medicinal chemistry. Anti-cancer agents.

[12]  H. Gogas,et al.  A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer , 2002, British Journal of Cancer.

[13]  H. DeLuca,et al.  A potent analog of 1alpha,25-dihydroxyvitamin D3 selectively induces bone formation. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Welsh,et al.  Role of Mitochondria and Caspases in Vitamin D-mediated Apoptosis of MCF-7 Breast Cancer Cells* , 2001, The Journal of Biological Chemistry.

[15]  S. Peleg,et al.  Regulation of ligand-induced heterodimerization and coactivator interaction by the activation function-2 domain of the vitamin D receptor. , 2000, Molecular endocrinology.

[16]  M. Haussler,et al.  Molecular modeling, affinity labeling, and site-directed mutagenesis define the key points of interaction between the ligand-binding domain of the vitamin D nuclear receptor and 1 alpha,25-dihydroxyvitamin D3. , 2000, Biochemistry.

[17]  L. Binderup,et al.  The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. , 2000, Cancer research.

[18]  N. Swamy,et al.  Development of an affinity-driven cross-linker: isolation of a vitamin D receptor associated factor. , 2000, Bioorganic & medicinal chemistry letters.

[19]  T. McDonnell,et al.  Printed in U.S.A. Copyright © 2000 by The Endocrine Society Calcitriol-Induced Apoptosis in LNCaP Cells Is Blocked By Overexpression of Bcl-2* , 1999 .

[20]  M. Holick,et al.  Mechanistic studies to evaluate the enhanced antiproliferation of human keratinocytes by 1alpha,25-dihydroxyvitamin D(3)-3-bromoacetate, a covalent modifier of vitamin D receptor, compared to 1alpha,25-dihydroxyvitamin D(3). , 1999, Archives of biochemistry and biophysics.

[21]  D. Feldman,et al.  Liarozole Acts Synergistically with 1α,25-Dihydroxyvitamin D3 to Inhibit Growth of DU 145 Human Prostate Cancer Cells by Blocking 24-Hydroxylase Activity. , 1999, Endocrinology.

[22]  D. Feldman,et al.  Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. , 1999, Endocrinology.

[23]  L. Binderup,et al.  EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro , 1998, British journal of pharmacology.

[24]  H. DeLuca,et al.  Current understanding of the molecular actions of vitamin D. , 1998, Physiological reviews.

[25]  K. Burnstein,et al.  Antiproliferative Effect of 1α,25-Dihydroxyvitamin D3 in Human Prostate Cancer Cell Line LNCaP Involves Reduction of Cyclin-Dependent Kinase 2 Activity and Persistent G1 Accumulation. , 1998, Endocrinology.

[26]  M. Haussler,et al.  The Nuclear Vitamin D Receptor: Biological and Molecular Regulatory Properties Revealed , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  C. Winder,et al.  The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. , 1997, Toxicology.

[28]  N. Swamy,et al.  Identification of the subdomain in the nuclear receptor for the hormonal form of vitamin D3, 1 alpha,25-dihydroxyvitamin D3, vitamin D receptor, that is covalently modified by an affinity labeling reagent. , 1997, Archives of biochemistry and biophysics.

[29]  M. Campbell,et al.  Toward therapeutic intervention of cancer by vitamin D compounds. , 1997, Journal of the National Cancer Institute.

[30]  N. Swamy,et al.  Affinity labeling of rat serum vitamin D binding protein. , 1996, Archives of biochemistry and biophysics.

[31]  J. Welsh,et al.  1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[32]  M. Haussler,et al.  Affinity Labeling of the 1,25-Dihydroxyvitamin D Receptor (*) , 1996, The Journal of Biological Chemistry.

[33]  L. Freedman,et al.  Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. , 1996, Genes & development.

[34]  R. Bouillon,et al.  Structure-function relationships in the vitamin D endocrine system. , 1995, Endocrine reviews.

[35]  D. Peehl,et al.  Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. , 1995, Endocrinology.

[36]  F. Sweet,et al.  Affinity labeling of hormone-specific proteins. , 1987, Endocrine reviews.

[37]  H. Green,et al.  Seria cultivation of strains of human epidemal keratinocytes: the formation keratinizin colonies from single cell is , 1975, Cell.

[38]  H Green,et al.  Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. , 1975, Cell.